AMENDMENTS TO THE CLAIMS

Amend the claims as indicated below.

1. (Currently amended) ~~Gene-~~ A gene transfer vector, comprising

(a) a promoter region consisting of nucleotides 453 to 2150 of SEQ ID NO: 1;

(b) a transgene or the cDNA of a transgene; and

(c) two multi-cloning sites (MCS) between which is the transgene.

2. (Currently amended) ~~Gene-~~ The gene transfer vector according to Claim 1, wherein the transgene is a therapeutic gene.

3. (Currently amended) ~~Gene-~~ The gene transfer vector according to Claim 1, wherein the transgene is a reporter gene.

4. to 5. (Canceled)

6. (Currently amended) ~~Gene-~~ The gene transfer vector according to Claim 1, wherein a regulating element is additionally inserted into the vector.

7. (Currently amended) ~~Gene-~~ The gene transfer vector according to Claim 1, wherein the multi-cloning sites (MCS) contain at least 3 enzyme restriction sites that do not cut within either of the transgene or the YB-1 promoter ~~interfaces for restriction enzymes~~.

8. (Currently amended) ~~Gene-~~ The gene transfer vector according to Claim 1, wherein the multi-cloning sites (MCS) each comprise between 5-10 restriction enzyme sites.

9. (Currently amended) ~~Gene~~ The gene transfer vector according to Claim 1, wherein the multi-cloning sites (MCS) for restriction enzymes contain no enzyme restriction sites occurring within the sequences of the YB-1 promoter.

10. (Currently amended) ~~Gene~~ The gene transfer vector according to Claim 1, wherein the multi-cloning sites (MCS) contain sticky enzyme restriction sites and blunt enzyme restriction sites for restriction enzymes.

11. to 15. (Canceled)

16. (Currently amended) The gene transfer vector of claim 1, wherein ~~it~~ the vector is in a form suitable for *in vivo* expression of the transgene.

17. (Canceled).

18. (Previously presented) A gene expression cassette comprising,

(a) a promoter region consisting of nucleotides 453 to 2150 of SEQ ID NO: 1;

(b) a transgene or the cDNA of a transgene; and

(c) two multi-cloning sites (MCS) between which is the transgene.

19. (Previously presented) The gene expression cassette of claim 18, further comprising adenoviral genomic sequences lacking the E1 and E3 regions of the adenoviral genome.

20. (Previously presented) The gene expression cassette of claim 18, further comprising replication-defective adenoviral genomic sequences, thereby providing a gene transfer vector suitable for the *in vivo* expression of a transgene.

21. (Previously presented) The gene expression cassette of claim 18, further comprising replication-defective adenoviral genomic sequences, thereby providing a gene transfer vector suitable for the *in vitro* expression of a transgene in cultured mammalian cells.

22. (New) A method for expressing in a mammal, a transgene comprising the gene transfer vector of claim 1, the method comprising,

(a) introducing the gene transfer vector of claim 1 into the circulatory system of the mammal, and

(b) determining the expression of the transgene being expressed from the YB-1 promoter.

23. (New) The method of claim 22, wherein the mammal is a mouse.

24. (New) The method of claim 22, wherein the vector is expressing a gene for a protein that can be measured in the mammal's blood or serum.

25. (New) The method of claim 22, wherein the transgene is a gene encoding a secretory protein.

26. (New) The method of claim 22, wherein the transgene is a gene normally expressed in liver cells.

27. (New) The method of claim 22, wherein the vector is expressed in proliferating cells.

28. (New) The method of claim 27, wherein the proliferating cells are hepatocytes.

29. (New) The method of claim 22, wherein the transgene is a gene encoding a α-1 antitrypsin.

30. (New) The method of claim 22, wherein the step of introducing the gene transfer vector into the circulatory system comprises intravenously administering the gene transfer vector of claim 1.